Mdxhealth Sa · NASDAQ:MDXH
Mdxhealth Sa — Investor Presentation (December 2020)
21 slides from Mdxhealth Sa's investor presentation, December 2020
Slide 1: Corporate Presentation December 2020
CORPORATE PRESENTATION December 2020
Slide 2: Forward Looking Statement
Forward Looking Statement This presentation contains forward-looking statements & estimates made by the management of the Company with respect to the anticipated future performance of MDxHealth & the market in which it operates. Such statements & estimates are based on various assumptions & assessme
Slide 3: Improving prostate cancer diagnosis via proprietary genomic technologies
Improving prostate cancer diagnosis via proprietary genomic technologies • Commercial-stage menu improves prostate cancer diagnosis and treatment while reducing costs • Restructuring of commercial focus has driven adoption, and tests are included in clinical guidelines • Proven business model with a
Slide 4: Experienced Leadership Team
Experienced Leadership Team Proven track record of success Miriam Reyes Joseph Sollee Michael K. McGarrity Ron Kalfus John Bellano Executive Vice President Executive Vice President Chief Executive Officer Chief Financial Officer Chief Commercial Officer Laboratory Operations Corp. Dev. & General Cou
Slide 5: Current Challenges with Diagnosing Prostate Cancer in the U.S.
Current Challenges with Diagnosing Prostate Cancer in the U.S. 2020 ACS Surveillance Research #1 Most Common Cancer in U.S. Men 3 million elevated PSA results annually(1-2) 191,930 of biopsies do not reveal 116,300 cancer and may lead to 78,300 62,100 60,190 60% increased complications and hospitali
Slide 6: U.S. Annual Market Opportunity
U.S. Annual Market Opportunity Prostate Cancer is the Most Common Cancer in American Men Who needs Who needs a Who needs a biopsy? repeat biopsy? treatment? 25M 500K 200K 3M PSA tests 33,350 Prostate New prostate Living with performed Estimated biopsies cancer cases prostate cancer Deaths performed
Slide 7: MDxHealth's Prostate Cancer Menu
MDxHealth’s Prostate Cancer Menu Clinical Pathway for Diagnosing Aggressive Prostate Cancer Improving the decision for Improving the decision for initial prostate biopsy repeat prostate biopsy Cancer Biopsy / Biopsy / Positive Positive Imaging Imaging Routine Screening No Cancer Negative Negative ©2
Slide 8: Improves Patient Selection Prior to Prostate Biopsy
Improves Patient Selection Prior to Prostate Biopsy The most highly predictive test to help identify men at low risk for aggressive prostate cancer At risk for aggressive cancer? Positive Biopsy Routinely Negative Monitor Abnormal PSA/DRE 95% NPV Binary Actionable Results for patient and HCP • Non-i
Slide 9: Robust Clinical Evidence
: Robust Clinical Evidence 12 published studies on genes and technology (> 3,500 patients) Analytical Validity Clinical Validity Clinical Utility Health Economics Pivotal Clinical Studies Hessels et al., Analytical Validation Translational Medicine Communications 2017 Haese et al., Clinically Valida
Slide 10: Improves Diagnostic Confidence of Biopsy Result
Improves Diagnostic Confidence of Biopsy Result The only epigenetic test to identify men at risk for aggressive prostate cancer 12-core needle biopsy could miss the mark Positive Biopsy Core Cancer Rebiopsy Field Effect Positive MRI Cancer Avoid Prostate Urethra Prostate Negative Biopsy Core Rebiops
Slide 11: Robust Clinical Evidence
: Robust Clinical Evidence Over 55 published studies on genes and technology (> 5,500 patients) Analytical Validity Clinical Validity Clinical Utility Health Economics Pivotal Clinical Studies Van Neste et al., Analytical Validation BMC Urology 2013 Partin et al., Validation of High NPV Journal of U
Slide 12: Clinical Guideline Inclusion
Clinical Guideline Inclusion 2012 2016 2018 2018 2020 PSA screening ConfirmMDx is PSA testing resumes MDxHealth tests SelectMDx is reduced/eliminated included in the due to US included in included in the due to US NCCN Early Preventive Services European NCCN Preventive Services Detection of Task For
Slide 13: Expanding Menu in the Prostate Cancer Diagnostic Pathway
Expanding Menu in the Prostate Cancer Diagnostic Pathway SCREENING PATIENT SELECTION DIAGNOSIS ACTIVE SURVEILLANCE (AS) Intervention Biopsy/ Biopsy Negative Imaging Biopsy decision Active surveillance AS monitoring Prostate Cancer Initial Low-Grade Monitor- PSA Screening Test Biopsy Prostate Cancer
Slide 14: AS-MDx Stratifies Patients for Active Surveillance vs Intervention
AS-MDx Stratifies Patients for Active Surveillance vs Intervention Positive Intervention 134K AS-MDx Est. Market size Active Negative (Men Annually) Surveillance Low-grade prostate cancer AS-MDx • Not all men diagnosed with localized prostate cancer benefit from intervention; some tumors are slow gr
Slide 15: Monitor-MDx Validates Continued Active Surveillance
Monitor-MDx Validates Continued Active Surveillance Positive Intervention Monitor- 1.5M MDx Est. Market size Continued Active Negative (Men Annually) Surveillance Under Active Surveillance (Low-grade cancer) Monitor-MDx • Patients under active surveillance are currently monitored by invasive and cos
Slide 16: Fundamentals In Place to Drive Sustained Growth
Fundamentals In Place to Drive Sustained Growth Strong Commercial Focus Proven Reimbursement Robust and Reliable and Presence Strategy Technology Leveraging direct sales force in U.S. ConfirmMDx covered by Medicare and Proprietary IP portfolio capable of commercial payers advancing our diagnostic pa
Slide 17: MDxHealth Adoption is Broad and Accelerating
MDxHealth Adoption is Broad and Accelerating • Considerable value in the current MDxHealth menu Diagnostic S-curve adoption model and customer base will drive significant revenue growth, as adoption progresses up the S-curve • By driving adoption through our high-quality physician base with the curr
Slide 18: Guideline Inclusion and Managed Care Contracts Payer Adoption
MDxHealth Guideline Inclusion and Managed Care Contracts 120 Payer Adoption SelectMDx in NCCN (2H20) Summary 100 ConfirmMDx and SelectMDx in EAU (1H18) 80 ConfirmMDx in NCCN 60 (1H16) ✓ 2016 NCCN Guidelines inclusion ✓ 96 payer contracts – 1H20 Launch 40 ConfirmMDx LCD (Medicare coverage) (2H14) Lau
Slide 19: MDxHealth is Clearly De-risked for Sustainable Growth & Value Creation
MDxHealth is Clearly De-risked for Sustainable Growth & Value Creation • Commercial execution: Best-in-class leadership, talent and process-based focus will drive growth • Operating discipline: Instituted through new leadership and all drivers of the P&L • Menu expansion: Clearly defined and initiat
Slide 20: Thank You
Thank You Global Operations General Inquiries [email protected] Investor Relations Contact LifeSci Advisors, LLC (IR & PR) U.S. Headquarters & Laboratory Global Headquarters R&D & Laboratory US +1 949 271 9223 15279 Alton Parkway, Ste 100 CAP Business Center Novio Tech Campus Transistorweg 5 Irvine
Slide 21: Presentation References
Presentation References SUMMARY REFERENCE CITATIONS Slide 5 – Current Challenges with Diagnosing Prostate Cancer in U.S. 1. NIH 8/20/2019 Website: https://seer.cancer.gov/statfacts/html/common.html. 2. MDxHealth management estimates 3. Moyer VA, U.S. Preventive Services Task Force. Screening for pro